[Real world use of statins for secondary prevention in patients with high risk coronary heart disease in China].

Zhonghua xin xue guan bing za zhi

Volumn 38, Issue 11, 2010, Pages 1033-1037

  Li, Hong Juan ^a   Liu, Jun ^b   Liu, Jing ^b   Wang, Wei ^b   Qin, Lan Ping ^b   Li, Yan ^b   Wang, Miao ^b   Sun, Jia Yi ^b   Qi, Yue ^b   Zhao, Dong ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CHINA; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE; SECONDARY PREVENTION;

AGED; CHINA; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; SECONDARY PREVENTION;

EID: 80054777962     PISSN: 02533758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)